0.05Open0.05Pre Close16 Volume3.89K Open Interest7.50Strike Price50.00Turnover322.11%IV13.74%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0728Delta0.1560Gamma288.67Leverage Ratio-0.1618Theta0.0000Rho-21.02Eff Leverage0.0004Vega
Annovis Bio Stock Discussion
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Annovis Bio Inc. (NYSE: ANVS) has announced promising early research results for its lead drug, buntanetap, in combination with other approved drugs for Alzheimer's disease (AD) treatment. While recent FDA-approved drugs like Leqembi and Kisunla may slow cognitive decline in AD patients, they do not improve cognition. Similarly, GLP-1 drugs, origi...
Larger Image: tradingview.com...
$ANVS
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
Annovis Bio Inc. (NYSE: ANVS) has filed three new patents for innovative combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.
Recent preclinical studies ...
No comment yet